Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Friday

Key Points

• Gyre Therapeutics is expected to report Q3 2026 results before the market opens on November 6. Analysts forecast a loss of $0.15 per share and revenue of $28.40 million.
• The company’s previous quarter missed EPS expectations, reporting a $0.12 per-share loss versus the expected $0.06 loss, although revenue exceeded forecasts at $29.11 million.
• Shares have fallen 9.6% and analysts remain cautious: the stock opened at $6.41, while its average analyst rating is “Reduce,” with one Hold and one Sell rating.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.15) per share and revenue of $28.40 million for the quarter. Parties are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The company had revenue of $29.11 million for the quarter, compared to analyst estimates of $26.49 million. On average, analysts expect Gyre Therapeutics to post ($0.61) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Gyre Therapeutics Stock Down 9.6%

Shares of NASDAQ GYRE opened at $6.41 on Friday. The firm has a market cap of $714.78 million, a price-to-earnings ratio of -30.52 and a beta of 1.89. The company's 50-day simple moving average is $6.78 and its 200-day simple moving average is $7.00. Gyre Therapeutics has a 52-week low of $5.44 and a 52-week high of $9.14.

Wall Street Analysts Forecast Growth

GYRE has been the topic of a number of research reports. Wall Street Zen lowered shares of Gyre Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, October 17th. Zacks Research upgraded Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 6th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Gyre Therapeutics in a report on Friday, August 7th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Gyre Therapeutics has an average rating of "Reduce".

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company's lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.